| A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation (NCT01068301) | St. Jude Children's Research Hospital | 2010-05-01 |
| SCRI Tissue Testing Registry (NCT00965861) | SCRI Development Innovations, LLC | 2010-05-01 |
| Lenalidomide and Prednisone in Low and Int-1 Myelodysplastic Syndrome (MDS) Non 5q MDS (NCT01133275) | H. Lee Moffitt Cancer Center and Research Institute | 2010-04-28 |
| Does Maitake Mushroom Extract Enhance Hematopoiesis in Myelodysplastic Patients? (NCT01099917) | Memorial Sloan Kettering Cancer Center | 2010-04-01 |
| Temsirolimus in Myelodysplastic Syndrome (MDS) (NCT01111448) | Technische Universität Dresden | 2010-04-01 |
| Clofarabine in High Risk Myelodysplastic Syndrome (MDS) (NCT01063257) | Groupe Francophone des Myelodysplasies | 2010-04-01 |
| Multi-center, Survival Data Collection in Subjects Previously Enrolled in Celgene Protocol CC-5013-MDS-003 (NCT01099267) | Celgene | 2010-03-01 |
| Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome (NCT01243476) | Fundación General de la Universidad de Salamanca | 2010-01-01 |
| Safety Study of Anti LewisY Chimeric Antigen Receptor in Myeloma, Acute Myeloid Leukemia or Myelodysplastic Syndrome (NCT01716364) | Peter MacCallum Cancer Centre, Australia | 2010-01-01 |
| Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS) (NCT00903760) | M.D. Anderson Cancer Center | 2010-01-01 |
| Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (NCT01048034) | Nordic MDS Group | 2010-01-01 |
| Escalation Study to Determine Bioavailability of a Single Oral Dose of Decitabine in Patients With Myelodysplastic Syndrome (MDS) (NCT00941109) | Eisai Inc. | 2009-12-01 |
| Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome (NCT01048619) | Traws Pharma, Inc. | 2009-12-01 |
| Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS) (NCT01062152) | Telik | 2009-11-01 |
| Ondansetron Versus Aprepitant Plus Ondansetron for Emesis (NCT00954941) | M.D. Anderson Cancer Center | 2009-11-01 |
| Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine (NCT00987480) | Memorial Sloan Kettering Cancer Center | 2009-09-25 |
| Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies (NCT00908167) | St. Jude Children's Research Hospital | 2009-09-01 |
| Erlotinib Study for Myelodysplastic Syndrome (MDS) (NCT00977548) | H. Lee Moffitt Cancer Center and Research Institute | 2009-09-01 |
| Clinical Relevance of DNMT and HDAC Gene SNP on the Response to Decitabine Therapy for Myelodysplastic Syndrome (NCT04515914) | Samsung Medical Center | 2009-09-01 |
| An Effectiveness and Safety Study of Decitabine in Patients With Myelodysplastic Syndrome (NCT01751867) | Xian-Janssen Pharmaceutical Ltd. | 2009-08-01 |
| T-cell Depleted Alternative Donor Transplantation (NCT00968864) | Wake Forest University Health Sciences | 2009-08-01 |
| Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor (NCT00967343) | Kiadis Pharma | 2009-08-01 |
| Trial of High Dose Lenalidomide in Patients With MDS and AML With Trilineage Dysplasia (NCT00867308) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2009-07-01 |
| Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry for Off-Label Transplant Use of Plerixafor (NCT01362985) | Genzyme, a Sanofi Company | 2009-07-01 |
| Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML) (NCT00831766) | H. Lee Moffitt Cancer Center and Research Institute | 2009-06-25 |
| A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT) for Primary Refractory and Relapsed Acute Myelogenous Leukemia (AML) (NCT00875693) | Weill Medical College of Cornell University | 2009-06-02 |
| MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia (NCT00911066) | Millennium Pharmaceuticals, Inc. | 2009-06-01 |
| Study of AR-67 (DB-67) in Myelodysplastic Syndrome (MDS) (NCT00956787) | Arno Therapeutics | 2009-06-01 |
| Revlimid in Transfusion Dependent Patients (NCT01178814) | Columbia University | 2009-06-01 |
| Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS) (NCT00903422) | GlaxoSmithKline | 2009-05-14 |
| Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY (NCT00809276) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2009-05-01 |
| Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk (NCT00906334) | Traws Pharma, Inc. | 2009-05-01 |
| PRO#0118: Decitabine Plus Mini Flu-Bu (NCT01455506) | Hackensack Meridian Health | 2009-05-01 |
| Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS) (NCT00882102) | M.D. Anderson Cancer Center | 2009-04-01 |
| A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies (NCT00807677) | Millennium Pharmaceuticals, Inc. | 2009-03-01 |
| Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS) (NCT00867061) | Traws Pharma, Inc. | 2009-03-01 |
| Unrelated Umbilical Cord Blood (UBC)Transplantation (NCT01768845) | West Virginia University | 2009-02-03 |
| SIMIDIS: Azacitidine and Beta Erythropoietin Treatment in Patients With Myelodysplastic Syndrome (NCT00495547) | PETHEMA Foundation | 2009-02-01 |
| A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q (NCT00885508) | Groupe Francophone des Myelodysplasies | 2009-02-01 |
| Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia (NCT00843882) | National Cancer Institute (NCI) | 2009-01-29 |
| Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia (NCT00818649) | Masonic Cancer Center, University of Minnesota | 2009-01-01 |
| Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML (NCT00854945) | Traws Pharma, Inc. | 2009-01-01 |
| RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS (NCT00819546) | Richard Stone, MD | 2009-01-01 |
| Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome (NCT00360672) | M.D. Anderson Cancer Center | 2009-01-01 |
| CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene (NCT00710892) | Baylor College of Medicine | 2008-12-01 |
| A Study for Dacogen Treatment in Patients With Myelodysplastic Syndrome (NCT01041846) | Janssen Korea, Ltd., Korea | 2008-12-01 |
| Efficacy and Safety of Lenalidomide in Combination With Cyclosporine A in Patients With Myelodysplastic Syndromes (NCT00840827) | Weill Medical College of Cornell University | 2008-12-01 |
| Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC) (NCT00822393) | medac GmbH | 2008-11-24 |
| Bendamustine in Acute Leukemia and MDS (NCT00790855) | M.D. Anderson Cancer Center | 2008-11-01 |
| Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation (NCT00795548) | Heinrich-Heine University, Duesseldorf | 2008-11-01 |
| Collection and Banking of Leukemia Cells MDS/AML (NCT00809367) | Dana-Farber Cancer Institute | 2008-10-01 |
| Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) (NCT00778375) | M.D. Anderson Cancer Center | 2008-10-01 |
| Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors (NCT00640796) | St. Jude Children's Research Hospital | 2008-09-01 |
| Blood Samples to Evaluate Biomarkers of Donor Chimerism (NCT00764829) | Fred Hutchinson Cancer Center | 2008-09-01 |
| Safety and Efficacy of Azacitidine, and Thalidomide in Higher Risk MDS (Myelodysplastic Syndrome) (NCT00704704) | Tel-Aviv Sourasky Medical Center | 2008-09-01 |
| Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies. (NCT00739141) | Memorial Sloan Kettering Cancer Center | 2008-08-12 |
| Deferoxamine for Iron Overload Before Allogeneic Stem Cell Transplantation (NCT00658411) | Dana-Farber Cancer Institute | 2008-08-01 |
| An Efficacy and Safety Study of Decitabine in Participants With Myelodysplastic Syndrome (MDS) (NCT00744757) | Johnson & Johnson Taiwan Ltd | 2008-08-01 |
| 5-Azacitidine in Low-risk Myelodysplastic Syndromes (MDSs) (NCT00897130) | Università degli Studi di Brescia | 2008-08-01 |
| Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT (NCT00709592) | Virginia Commonwealth University | 2008-07-21 |
| A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) Patients (NCT00699842) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2008-07-01 |
| 5-Azacytidine Prior to Allogeneic Stem Cell Transplant in High Risk Myelodysplastic Syndrome (NCT00721214) | Virginia Commonwealth University | 2008-07-01 |
| A Study of JNJ-30979754 (Decitabine) in Patients With Myelodysplastic Syndrome (NCT00796003) | Janssen Pharmaceutical K.K. | 2008-07-01 |
| Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer (NCT00723099) | Fred Hutchinson Cancer Center | 2008-06-25 |
| Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant (NCT00697684) | Beth Israel Deaconess Medical Center | 2008-06-01 |
| INCB018424 in Patients With Advanced Hematologic Malignancies (NCT00674479) | M.D. Anderson Cancer Center | 2008-05-12 |
| A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) (NCT00619099) | Eisai Inc. | 2008-05-01 |
| A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS (NCT00656448) | M.D. Anderson Cancer Center | 2008-03-01 |
| Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR (NCT01611298) | Robert Krance | 2008-03-01 |
| Rituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCT (NCT00648037) | Memorial Sloan Kettering Cancer Center | 2008-03-01 |
| Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation (NCT00620633) | Memorial Sloan Kettering Cancer Center | 2008-02-08 |
| Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders (NCT00588991) | National Cancer Institute (NCI) | 2008-02-04 |
| Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome (NCT00968071) | M.D. Anderson Cancer Center | 2008-02-01 |
| Palifermin After Haploidentical PBSCT (NCT00570999) | European Society for Blood and Marrow Transplantation | 2008-02-01 |
| Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transplant (NCT00674427) | University of Pennsylvania | 2008-01-01 |
| Cephalon Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndrome (NCT00621023) | Duke University | 2007-11-01 |
| The Role of Erlotinib an Epidermal Growth Factor Receptor (EGFR) Inhibitor in the Treatment of Myelodysplastic Syndrome (NCT00570375) | University of Cincinnati | 2007-11-01 |
| Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System (NCT00520130) | National Cancer Institute (NCI) | 2007-10-30 |
| Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen (NCT00556452) | University of Michigan Rogel Cancer Center | 2007-10-01 |
| Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias (NCT00852709) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2007-09-01 |
| Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome (NCT01311258) | University of Rochester | 2007-08-01 |
| Study of Temozolomide in Previously Untreated Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Participants With Low O6-Methylguanine Methyltransferase (MGMT) Expression (P05052) (NCT00687323) | Merck Sharp & Dohme LLC | 2007-07-30 |
| Cord Blood Expansion on Mesenchymal Stem Cells (NCT00498316) | M.D. Anderson Cancer Center | 2007-07-03 |
| Study With Intravenous Busulfan And Fludarabine Myeloablative Conditioning Regimen For HLA Identical Sibling Donor HSCT (NCT01683123) | Grupo Espanol de trasplantes hematopoyeticos y terapia celular | 2007-07-01 |
| Abdominal Obesity and Cardiovascular Risk Factors in Women Who Survived Cancer or a Related Illness Following Total Body Irradiation and Stem Cell Transplant (NCT00510315) | Memorial Sloan Kettering Cancer Center | 2007-07-01 |
| Treosulfan-based Conditioning for Transplantation in AML/MDS (NCT00491634) | Dr. Avichai Shimoni MD | 2007-06-01 |
| Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD (NCT00539695) | Baylor College of Medicine | 2007-06-01 |
| Phase 2, Open-Label, Multi-Dose Study of Panhematin in Patients With MDS (NCT00467610) | Rush University Medical Center | 2007-05-01 |
| A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (NCT00458159) | Celgene | 2007-05-01 |
| Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation (NCT00626626) | Milton S. Hershey Medical Center | 2007-05-01 |
| The Efficacy of Coenzyme Q10 And Curcumin in Patients With Myelodysplastic Syndromes (NCT00247026) | Hadassah Medical Organization | 2007-04-01 |
| A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine (NCT00741234) | S*BIO | 2007-04-01 |
| Effects of Antithymocyte Globulin in Adults With Myelodysplastic Syndrome (NCT00466843) | Office of Rare Diseases (ORD) | 2007-04-01 |
| Enhancing Graft vs Leukemia Via Delayed Ex-Vivo Co-Stimulated DLI After Non-Myeloablative Stem Cell Transplantation (NCT00374933) | Abramson Cancer Center at Penn Medicine | 2007-04-01 |
| Intraosseous Infusion of Unrelated Cord Blood Grafts (NCT00967525) | Emory University | 2007-03-01 |
| The Role of Erythropoietin in Myelodysplastic Syndrome (NCT00723112) | University of Utah | 2007-02-01 |
| Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy (NCT00433745) | National Heart, Lung, and Blood Institute (NHLBI) | 2007-02-01 |
| Effectiveness of Protected Environment Rooms for AML and MDS (NCT00443300) | M.D. Anderson Cancer Center | 2007-01-01 |
| Treatment of Imminent Haematological Relapse in Patients With AML and MDS Following Allogeneic Stem Cell Transplantation With 5-azacitidine (Vidaza®) (NCT00422890) | Technische Universität Dresden | 2007-01-01 |
| A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status (NCT00462761) | Daiichi Sankyo | 2007-01-01 |